Last reviewed · How we verify
Colorectal Cancer
Approved treatments
Pipeline
- PD-0325901 · Pfizer Inc. — discontinued
Clinical guidelines
- FDA label — 1L
ERBITUX in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC). - FDA label — 2L
ERBITUX in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy. - FDA label — 3L+
ERBITUX as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: